Clinical trials: Small Cell Carcinoma of Lung
Non-Small Cell Lung Cancer
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
The purpose of this trail is to evaluate the performance of Genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.
- Trial name
- NCT05023746
- Testing
- Genetron lung cancer panel
- Where
- 4 sites in China
- Volunteers
- 1,052 people
- Sponsor
- Genetron Health
HIV Infection, Recurrent Non-Small Cell Lung Carcinoma
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
This phase I trial studies the side effects and best dose of erlotinib hydrochloride in treating non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery in patients with human…
- Conditions
- HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02134886
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
Multicenter prospective assessment of MET concordance and tumor gene profiling in treatment-naïve NSCLC
- Trial name
- Genomet (NCT07613424)
- Testing
- NGS testing, MET IHC testing, PD-L1 and Her2 testing
- Where
- 51 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a chemotherapy and radiotherapy sensitive tumor, but with very high rates of relapse and metastasis, resulting in a very poor outcome.
- Trial name
- NCT01173523
- Testing
- STA-9090
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- David M. Jackman, MD
Lung Cancer
Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and prevent the spread of cancer to the brain. It is not yet known if standard-dose radiation therapy is more effective than high-dose radiation therapy in…
- Trial name
- NCT00005062
- Testing
- radiation therapy
- Where
- 93 sites in United States, Australia and 26 more
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non-small Cell Lung Cancer
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Study IPI-504-15 is a Phase 1b/2 clinical trial to evaluate the safety and efficacy of retaspimycin HCl (IPI-504) plus everolimus in patients with KRAS mutant Non-small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01427946
- Testing
- IPI-504, Everolimus
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer
Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body, and protect your normal tissue.
- Trial name
- HUM15709 (NCT01190527)
- Testing
- FDG-PET
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lung Cancer (NSCLC), Lung Cancer (SCLC)
Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung
This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.
- Trial name
- PRACTICAL (NCT07202260)
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- The Christie NHS Foundation Trust
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Non-small Cell Lung Cancer NSCLC
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients…
- Trial name
- ORION (NCT03775486)
- Testing
- Durvalumab, Olaparib, Nab-paclitaxel+carboplatin
- Where
- 68 sites in United States, Belgium and 10 more
- Volunteers
- 401 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult…
- Trial name
- NCT06862869
- Testing
- Alectinib
- Where
- 44 sites in China
- Volunteers
- 800 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Multimodal Hypoxia Imaging and Intensity Modulated Radiotherapy for Inoperable Non-small-cell Lung Cancer
Radiotherapy, preferably combined with chemotherapy, is the treatment standard for locally advanced, unresectable non-small cell lung cancer (NSCLC).
- Trial name
- HIL (NCT01617980)
- Testing
- Multimodal hypoxia imaging
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- German Cancer Research Center
Non-small Cell Lung Cancer
Comparative Study of the Hypoxia Measured in FAZA and F-miso PET/CT Scan in Patients With Non-small Cell Lung Cancer
The purpose of the study is to compare the intratumoral biodistribution of FAZA and F-miso in patients with non-small cell lung cancer and correlate the results of PET scans with immunohistochemistry.
- Trial name
- RTEP6 (NCT02490696)
- Testing
- Miso PET scan, FAZA PET scan
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Henri Becquerel
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer Metastatic
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today.
- Trial name
- DICIPLE (NCT03469960)
- Testing
- Ipilimumab, Nivolumab
- Where
- 47 sites in France
- Volunteers
- 265 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
NSCLC, Stage III
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.
- Trial name
- NCT05611879
- Testing
- Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC), Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Lung Adenocarcinoma, Lymph Node Metastasis
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1018. The goal of this clinical trial is to confirm the theraputic effect of selective lymph node dissection for cT1N0M0…
- Trial name
- NCT06031246
- Testing
- Selective Lymph Node Dissection
- Where
- China
- Volunteers
- 634 people
- Sponsor
- Fudan University
Non Small Cell Lung Cancer, Pulmonary Metastases
Radiofrequency Ablation of Pulmonary Tumors Response Evaluation
The study hypothesis is that the radiofrequency (RF) ablation is a safe and effective treatment for malignant lung tumors.
- Trial name
- RAPTURE (NCT00690703)
- Testing
- RF ablation (Rita Medical Systems Model 1500x)
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 106 people
- Sponsor
- Angiodynamics, Inc.
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of pembrolizumab when given together with stereotactic body radiation therapy or non-stereotactic wide-field radiation therapy (conventional radiation…
- Conditions
- Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02444741
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
The purpose of this study is to describe the clinical and health-related outcomes of amivantamab-containing regimens for the treatment of common epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC…
- Trial name
- LEPIDOPTERA (NCT07230691)
- Where
- 90 sites in Austria, Belgium and 6 more
- Volunteers
- 380 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.